bumetanide has been researched along with Autism Spectrum Disorder in 22 studies
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mechanism-based treatments such as bumetanide are being repurposed for autism spectrum disorder." | 9.69 | Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder. ( Avramiea, AE; Bruining, H; Cristian, G; Eijkemans, MJC; Gerver, C; Hardstone, R; Houtman, SJ; Jan van der Wilt, G; Juarez-Martinez, EL; Linkenkaer-Hansen, K; Mansvelder, HD; Oranje, B; Simpraga, S; Sprengers, JJ; van Andel, DM, 2023) |
| "The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi-center, randomized, double-blind, placebo-controlled phase III trials; one enrolled patients aged 7-17 years (SIGN 1 trial) and the other enrolled younger patients aged 2-6 years (SIGN 2)." | 9.69 | Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies. ( Albarran, C; Ben Ari, Y; Crutel, V; Fuentes, J; Georgoula, C; Lambert, E; Marret, S; Oliveira, G; Parellada, M; Pénélaud, PF; Ravel, D, 2023) |
| "With the current limited drug therapy for the core symptoms of autism spectrum disorder (ASD), we herein report a randomized, double-blind, placebo-controlled trial to investigate the efficacy, safety, and potential neural mechanism of bumetanide in children with ASD aged 3-6 years old." | 9.41 | Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. ( Dai, Y; Deng, S; Du, X; Feng, J; He, H; Ji, Y; Langley, C; Li, F; Li, WG; Liu, X; Luo, Q; Sahakian, BJ; Tang, Y; Wang, K; Yu, J; Zhang, J; Zhang, L; Zhou, X, 2021) |
| "Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD)." | 9.41 | Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. ( Bruining, H; Keijzer-Veen, MG; Lilien, MR; Oranje, B; Scheepers, FE; Schulp, AJA; Sprengers, JJ; van Andel, DM; Zuithoff, NPA, 2021) |
| "Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models." | 9.34 | Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. ( Dai, Y; Deng, S; Du, X; Feng, J; Huang, CC; Ji, Y; Li, F; Lin, CP; Luo, Q; Sahakian, BJ; Shen, C; Tang, Y; Wang, K; Xu, M; Yu, J; Zhang, L, 2020) |
| "To evaluate clinical trials using bumetanide in autism spectrum disorder (ASD) treatment." | 9.01 | Bumetanide for Autism Spectrum Disorder in Children: A Review of Randomized Controlled Trials. ( Gales, BJ; Gales, MA; James, BJ, 2019) |
| "Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system." | 8.12 | The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder. ( Dai, Y; He, H; Langley, C; Li, F; Li, Q; Li, WG; Luo, Q; Sahakian, BJ; Shan, H; Yao, Y; Yu, J; Zhang, L, 2022) |
| "The specific NKCC1 cotransporter antagonist, bumetanide, attenuates the severity of Autism Spectrum Disorders (ASD), and many neurodevelopmental or neurodegenerative disorders in animal models and clinical trials." | 8.12 | A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders. ( Ben-Ari, Y; Delpire, E, 2022) |
| "Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC." | 6.94 | Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. ( Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020) |
| "The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi-center, randomized, double-blind, placebo-controlled phase III trials; one enrolled patients aged 7-17 years (SIGN 1 trial) and the other enrolled younger patients aged 2-6 years (SIGN 2)." | 5.69 | Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies. ( Albarran, C; Ben Ari, Y; Crutel, V; Fuentes, J; Georgoula, C; Lambert, E; Marret, S; Oliveira, G; Parellada, M; Pénélaud, PF; Ravel, D, 2023) |
| "With the current limited drug therapy for the core symptoms of autism spectrum disorder (ASD), we herein report a randomized, double-blind, placebo-controlled trial to investigate the efficacy, safety, and potential neural mechanism of bumetanide in children with ASD aged 3-6 years old." | 5.41 | Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. ( Dai, Y; Deng, S; Du, X; Feng, J; He, H; Ji, Y; Langley, C; Li, F; Li, WG; Liu, X; Luo, Q; Sahakian, BJ; Tang, Y; Wang, K; Yu, J; Zhang, J; Zhang, L; Zhou, X, 2021) |
| "Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD)." | 5.41 | Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. ( Bruining, H; Keijzer-Veen, MG; Lilien, MR; Oranje, B; Scheepers, FE; Schulp, AJA; Sprengers, JJ; van Andel, DM; Zuithoff, NPA, 2021) |
| "Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models." | 5.34 | Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. ( Dai, Y; Deng, S; Du, X; Feng, J; Huang, CC; Ji, Y; Li, F; Lin, CP; Luo, Q; Sahakian, BJ; Shen, C; Tang, Y; Wang, K; Xu, M; Yu, J; Zhang, L, 2020) |
| "Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system." | 4.12 | The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder. ( Dai, Y; He, H; Langley, C; Li, F; Li, Q; Li, WG; Luo, Q; Sahakian, BJ; Shan, H; Yao, Y; Yu, J; Zhang, L, 2022) |
| "Before we elaborate on the postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, we would like to acknowledge the crucial pioneering work on the γ-aminobutyric acid (GABA) developmental sequence by Dr." | 4.02 | Dr. Sprengers et al. Reply. ( Bruining, H; Sprengers, JJ; van Andel, DM, 2021) |
| "Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC." | 2.94 | Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. ( Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020) |
| "Autism spectrum disorder is defined by two core symptoms: a deficit in social communication and the presence of repetitive behaviors and/or restricted interests." | 2.58 | Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. ( Frye, RE, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 16 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Juarez-Martinez, EL | 1 |
| Sprengers, JJ | 4 |
| Cristian, G | 1 |
| Oranje, B | 3 |
| van Andel, DM | 4 |
| Avramiea, AE | 1 |
| Simpraga, S | 1 |
| Houtman, SJ | 1 |
| Hardstone, R | 1 |
| Gerver, C | 1 |
| Jan van der Wilt, G | 1 |
| Mansvelder, HD | 1 |
| Eijkemans, MJC | 1 |
| Linkenkaer-Hansen, K | 1 |
| Bruining, H | 4 |
| Georgoula, C | 2 |
| Ferrin, M | 1 |
| Pietraszczyk-Kedziora, B | 1 |
| Hervas, A | 2 |
| Marret, S | 3 |
| Oliveira, G | 3 |
| Rosier, A | 3 |
| Crutel, V | 3 |
| Besse, E | 1 |
| Severo, CA | 1 |
| Ravel, D | 4 |
| Fuentes, J | 3 |
| Li, Q | 1 |
| Zhang, L | 3 |
| Shan, H | 1 |
| Yu, J | 3 |
| Dai, Y | 3 |
| He, H | 2 |
| Li, WG | 3 |
| Langley, C | 2 |
| Sahakian, BJ | 3 |
| Yao, Y | 1 |
| Luo, Q | 3 |
| Li, F | 4 |
| Lv, H | 1 |
| Gu, X | 1 |
| Shan, X | 1 |
| Zhu, T | 1 |
| Ma, B | 1 |
| Zhang, HT | 1 |
| Bambini-Junior, V | 1 |
| Zhang, T | 1 |
| Gao, X | 1 |
| Delpire, E | 1 |
| Ben-Ari, Y | 4 |
| Phillips, AG | 1 |
| Zhou, X | 1 |
| Ji, Y | 2 |
| Wang, K | 2 |
| Du, X | 2 |
| Liu, X | 1 |
| Tang, Y | 2 |
| Deng, S | 2 |
| Zhang, J | 1 |
| Feng, J | 2 |
| Parellada, M | 2 |
| Albarran, C | 1 |
| Lambert, E | 2 |
| Pénélaud, PF | 2 |
| Ben Ari, Y | 1 |
| Feng, JY | 1 |
| Li, HH | 1 |
| Wang, B | 1 |
| Shan, L | 1 |
| Jia, FY | 1 |
| Huang, CC | 1 |
| Xu, M | 1 |
| Shen, C | 1 |
| Lin, CP | 1 |
| Scheepers, FE | 2 |
| Jansen, FE | 1 |
| Zuithoff, NPA | 1 |
| Keijzer-Veen, MG | 1 |
| Schulp, AJA | 1 |
| Lilien, MR | 1 |
| Albarrán Severo, C | 1 |
| Kyaga, S | 1 |
| Gouttefangeas, S | 1 |
| Bertrand, M | 1 |
| Falissard, B | 1 |
| Vitiello, B | 1 |
| Lemonnier, E | 2 |
| Rabiei, H | 2 |
| Makowski, D | 1 |
| Hadjikhani, N | 1 |
| Frye, RE | 1 |
| James, BJ | 1 |
| Gales, MA | 1 |
| Gales, BJ | 1 |
| Cloarec, R | 1 |
| Riffault, B | 1 |
| Dufour, A | 1 |
| Gouty-Colomer, LA | 1 |
| Dumon, C | 1 |
| Guimond, D | 1 |
| Bonifazi, P | 1 |
| Eftekhari, S | 1 |
| Lozovaya, N | 1 |
| Ferrari, DC | 1 |
| Merner, ND | 1 |
| Mercado, A | 1 |
| Khanna, AR | 1 |
| Hodgkinson, A | 1 |
| Bruat, V | 1 |
| Awadalla, P | 1 |
| Gamba, G | 1 |
| Rouleau, GA | 1 |
| Kahle, KT | 1 |
| Bou Khalil, R | 1 |
| Villeneuve, N | 1 |
| Sonie, S | 1 |
| Serret, S | 1 |
| Roue, M | 1 |
| Brosset, P | 1 |
| Viellard, M | 1 |
| Bernoux, D | 1 |
| Rondeau, S | 1 |
| Thummler, S | 1 |
2 reviews available for bumetanide and Autism Spectrum Disorder
| Article | Year |
|---|---|
Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents.
Topics: Autism Spectrum Disorder; Bumetanide; Disease Progression; Fecal Microbiota Transplantation; Humans; | 2018 |
Bumetanide for Autism Spectrum Disorder in Children: A Review of Randomized Controlled Trials.
Topics: Adolescent; Autism Spectrum Disorder; Bumetanide; Child; Child, Preschool; Female; Humans; Male; Ran | 2019 |
9 trials available for bumetanide and Autism Spectrum Disorder
| Article | Year |
|---|---|
Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder.
Topics: Autism Spectrum Disorder; Bumetanide; Electroencephalography; Humans; Treatment Outcome | 2023 |
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Double-Blind Method; Fem | 2023 |
Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Child, Preschool; gamma-Aminobutyric | 2021 |
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Double-Blind Method; Hum | 2023 |
Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Child, Preschool; gamma-Aminobutyric | 2020 |
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
Topics: Adolescent; Autism Spectrum Disorder; Bumetanide; Child; Disease Susceptibility; Duration of Therapy | 2020 |
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Double-Blind Method; Humans; Membran | 2021 |
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Topics: Adolescent; Autism Spectrum Disorder; Bumetanide; Child; Child, Preschool; Double-Blind Method; Huma | 2021 |
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.
Topics: Adolescent; Anorexia; Asthenia; Autism Spectrum Disorder; Bumetanide; Child; Child, Preschool; Dehyd | 2017 |
11 other studies available for bumetanide and Autism Spectrum Disorder
| Article | Year |
|---|---|
The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Child, Preschool; Cytokines; gamma-A | 2022 |
Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder.
Topics: Animals; Autism Spectrum Disorder; Brain; Bumetanide; Disease Models, Animal; Mice; Mice, Inbred Str | 2022 |
A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders.
Topics: Animals; Autism Spectrum Disorder; Bumetanide; Solute Carrier Family 12, Member 2 | 2022 |
Placing old wine into new bottles: successful repurposing of bumetanide for treatment of autism spectrum disorder.
Topics: Autism Spectrum Disorder; Bumetanide; Humans; Sodium Potassium Chloride Symporter Inhibitors | 2021 |
Successive clinical application of vitamin D and bumetanide in children with autism spectrum disorder: A case report.
Topics: Autism Spectrum Disorder; Bumetanide; Child, Preschool; Dietary Supplements; Female; Humans; Vitamin | 2020 |
Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Communication; Humans | 2021 |
Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Humans | 2021 |
Dr. Sprengers et al. Reply.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; gamma-Aminobutyric Acid; Humans; N | 2021 |
Pyramidal neuron growth and increased hippocampal volume during labor and birth in autism.
Topics: Animals; Animals, Newborn; Autism Spectrum Disorder; Bumetanide; Dendrites; Disease Models, Animal; | 2019 |
Gain-of-function missense variant in SLC12A2, encoding the bumetanide-sensitive NKCC1 cotransporter, identified in human schizophrenia.
Topics: Animals; Autism Spectrum Disorder; Bumetanide; Cohort Studies; Intellectual Disability; Membrane Pot | 2016 |
Is insulin growth factor-1 the future for treating autism spectrum disorder and/or schizophrenia?
Topics: Animals; Autism Spectrum Disorder; Brain; Bumetanide; Child; Child, Preschool; Chlorides; Endocannab | 2017 |